These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 34254284)
1. Efficacy of expressions of Arg-1, Hep Par-1, and CK19 in the diagnosis of the primary hepatocellular carcinoma subtypes and exclusion of the metastases. Atta IS Histol Histopathol; 2021 Sep; 36(9):981-993. PubMed ID: 34254284 [TBL] [Abstract][Full Text] [Related]
2. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Radwan NA; Ahmed NS Diagn Pathol; 2012 Oct; 7():149. PubMed ID: 23111165 [TBL] [Abstract][Full Text] [Related]
3. Hepatocyte differentiation markers in adenocarcinoma of the prostate: hepatocyte paraffin 1 but not arginase-1 is specifically expressed in a subset of prostatic adenocarcinoma. Giedl J; Büttner-Herold M; Wach S; Wullich B; Hartmann A; Agaimy A Hum Pathol; 2016 Sep; 55():101-7. PubMed ID: 27184483 [TBL] [Abstract][Full Text] [Related]
4. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Timek DT; Shi J; Liu H; Lin F Am J Clin Pathol; 2012 Aug; 138(2):203-10. PubMed ID: 22904131 [TBL] [Abstract][Full Text] [Related]
5. Arginase-1 is a more sensitive marker than HepPar-1 and AFP in differential diagnosis of hepatocellular carcinoma from nonhepatocellular carcinoma. Sang W; Zhang W; Cui W; Li X; Abulajiang G; Li Q Tumour Biol; 2015 May; 36(5):3881-6. PubMed ID: 25577247 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and differential diagnosis of hepatocellular carcinoma in extrahepatic metastases. Chen D; Li Z; Song Q; Qian L; Xie B; Zhu J Medicine (Baltimore); 2018 Dec; 97(50):e13356. PubMed ID: 30557986 [TBL] [Abstract][Full Text] [Related]
7. The strength of cytomorphology and efficacy of immuno-cytochemistry in distinguishing hepatocellular carcinoma from its mimics on fine-needle aspiration cytology. Chikhale M; Toi PC; Siddaraju N; Ananthakrishnan R Diagn Cytopathol; 2021 Jul; 49(7):864-875. PubMed ID: 33929782 [TBL] [Abstract][Full Text] [Related]
8. Utilization of antihepatocyte clone OCH1E5 (Hep Par 1) in histological evaluation of liver tumors. Amarapurkar AD; Rege JD; Joshi AS; Vaiphei K; Amarapurkar DN Indian J Pathol Microbiol; 2006 Jul; 49(3):341-4. PubMed ID: 17001880 [TBL] [Abstract][Full Text] [Related]
9. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Yan BC; Gong C; Song J; Krausz T; Tretiakova M; Hyjek E; Al-Ahmadie H; Alves V; Xiao SY; Anders RA; Hart JA Am J Surg Pathol; 2010 Aug; 34(8):1147-54. PubMed ID: 20661013 [TBL] [Abstract][Full Text] [Related]
10. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors]. Li J; Wei L Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815 [TBL] [Abstract][Full Text] [Related]
11. Arginase-1: a highly specific marker separating pancreatic adenocarcinoma from hepatocellular carcinoma. Fatima N; Cohen C; Siddiqui MT Acta Cytol; 2014; 58(1):83-8. PubMed ID: 24281232 [TBL] [Abstract][Full Text] [Related]
12. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas. Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860 [TBL] [Abstract][Full Text] [Related]
13. Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens. Moudi B; Mahmoudzadeh-Sagheb H; Heidari Z BMC Res Notes; 2020 Aug; 13(1):388. PubMed ID: 32854754 [TBL] [Abstract][Full Text] [Related]
14. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection. Jin Y; Liang ZY; Zhou WX; Zhou L J Invest Surg; 2018 Oct; 31(5):412-419. PubMed ID: 28758812 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of glypican-3, arginase-1 and hepatocyte paraffin antigen -1 in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Wang C; Shao X; Zhang X; Xie C; Yu J; Xu X; Yang J; Li Y; Xu W Transl Cancer Res; 2020 Jan; 9(1):128-136. PubMed ID: 35117166 [TBL] [Abstract][Full Text] [Related]
16. [Role of arginase-1 expression in distinguishing hepatocellular carcinoma from non-hepatocellular tumors]. Sang W; Gulinar A; Wang CH; Sheng WQ; Maiweilidan Y; Zhang W Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):538-42. PubMed ID: 24246920 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver. Ibrahim TR; Abdel-Raouf SM Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409 [TBL] [Abstract][Full Text] [Related]
18. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. McKnight R; Nassar A; Cohen C; Siddiqui MT Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472 [TBL] [Abstract][Full Text] [Related]
19. A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative. Clark I; Shah SS; Moreira R; Graham RP; Wu TT; Torbenson MS; Chandan V Hum Pathol; 2017 Nov; 69():90-95. PubMed ID: 28970136 [TBL] [Abstract][Full Text] [Related]
20. Well differentiated arginase-1 negative hepatocellular carcinoma. Obiorah IE; Chahine J; Park BU; Ko K; deGuzman J; Kallakury B Transl Gastroenterol Hepatol; 2019; 4():66. PubMed ID: 31620648 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]